N. Malkova

发表

[The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].

A. Boyko, E. Evdoshenko, E. Popova, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

D. Arnold, L. Kappos, D. Zafeiriou, 2021, The Lancet Neurology.

[A retrospective analysis of the effect of pregnancy on the course of multiple sclerosis].

S. Sivertseva, A. Boyko, E. Popova, 2015, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Association between polymorphisms of cytokine genes and the rate of multiple sclerosis progression].

M. Filipenko, D. Korobko, N. Malkova, 2012, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Clinical recommendations on the use of alemtuzumab (lemtrada)].

S. Sivertseva, M. Zakharova, A. Boyko, 2017, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists].

S. Sivertseva, O. Boyko, A. Boyko, 2018, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Study of changes in perfusion in the foci of demyelination in multiple sclerosis by perfusion MRI

Y. Stankevich, D. Korobko, A. Tulupov, 2021, Diagnostic radiology and radiotherapy.

[Provision of alemtuzumab safety is one of the main components of pharmacovigilance].

S. Sivertseva, M. Zakharova, A. Boyko, 2018, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

[Susac syndrome, review and clinical case].

D. Korobko, N. Malkova, I. Vergunova, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Use of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis

M. Filipenko, N. Tikunova, D. Korobko, 2016, Immunogenetics.

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia

S. Sivertseva, G. Makshakov, M. Shumilina, 2019, PloS one.

Polymorphic Variants of Immune Response Genes as a Risk Factor for the Development of Primary Progressive Multiple Sclerosis

L. I. Volkova, S. Sivertseva, N. Baulina, 2018, Neuroscience and Behavioral Physiology.

Genome-wide significant association with seven novel multiple sclerosis risk loci

A. Alcina, F. Matesanz, X. Montalban, 2015, Journal of Medical Genetics.

[Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study].

S. Sivertseva, N. Khachanova, D. Korobko, 2022, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis].

A. Boyko, K. Bakhtiyarova, N. Malkova, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Polymorphic Variants of Immune Response Genes as a Risk Factor for the Development of Primary Progressive Multiple Sclerosis

O. Favorova, S. Sivertseva, N. Baulina, 2018, Neuroscience and Behavioral Physiology.

[Polymorphic variants of the immune response genes as risk factors for primary progressive multiple sclerosis].

O. Favorova, S. Sivertseva, A. Boyko, 2017, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab].

I. Pronin, S. Sivertseva, A. Boiko, 2016, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Denny J. Padgett, Adam L. Comer, Yi-Chung Lee, 2023, The Lancet Neurology.

[Primary progressive multiple sclerosis: current issues of timely diagnosis].

A. Belova, S. Sivertseva, A. Boyko, 2017, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Clinical recommendations on the use of teriflunomide].

A. Belova, S. Sivertseva, A. Boiko, 2016, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Association of SNPs of CD40 Gene with Multiple Sclerosis in Russians

Y. Aulchenko, F. Platonov, V. Puzyrev, 2013, PloS one.

Polymorphic locus rs10492972 of the KIF1B gene association with multiple sclerosis in Russia: case control study.

S. A. Babenko, F. Platonov, M. Filipenko, 2011, Molecular genetics and metabolism.

[Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis].

S. Sivertseva, A. Boiko, M. Zakharova, 2017, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].

S. Sivertseva, M. Zakharova, O. Boyko, 2023, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova.

[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].

O. Boyko, N. Totolyan, F. Khabirov, 2022, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.